Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Metrics to compare | SNDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSNDXPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.0x | −3.1x | −0.6x | |
PEG Ratio | 0.16 | −0.01 | 0.00 | |
Price/Book | 3.7x | 3.3x | 2.6x | |
Price / LTM Sales | 454.4x | 9.4x | 3.2x | |
Upside (Analyst Target) | 86.7% | 296.2% | 47.4% | |
Fair Value Upside | Unlock | 18.6% | 6.2% | Unlock |